EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Lebrikizumab-lbkz for the Treatment of Atopic Dermatitis: A Drug Review

Danial Nasim iD, Brett Shaffer, Steven R Feldman

Annals of Pharmacotherapy · 2026-07 · 60 (7) · 710-714

DOI: 10.1177/10600280251402987 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Annals of Pharmacotherapy, online erschienen am 26.12.2025. Verfasst von Danial Nasim und 2 weiteren Autor:innen. Beteiligte Einrichtung: Center for Dermatology Research, Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Dermatitis, Atopic, Dermatologic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lebrikizumab is a monoclonal antibody targeting interleukin 13 (IL-13), a key cytokine in the pathogenesis of atopic dermatitis (AD). It was approved by the Food and Drug Administration (FDA) in 2024 for the treatment of moderate-to-severe AD in patients aged ≥12 years. Data sources: A literature search was conducted through October 2025 using PubMed and ClinicalTrials.gov with the terms “lebrikizumab,” “Ebglyss,” “lebrikizumab clinical trials,” and “lebrikizumab atopic dermatitis.” Phase I to III clinical trials, post-approval studies, and FDA package insert were reviewed. Study selection and data extraction: Trials evaluating lebrikizumab in patients with AD were included. Data were extracted on study design, pharmacology, efficacy outcomes, and safety events. One phase I, 2 phase II, and 6 phase III studies were summarized along with real-world evidence. Data synthesis: Lebrikizumab had dose-dependent reductions in AD severity and pruritus, with improvements observed as early as day 2. Across phase III trials, 33% to 43% of lebrikizumab-treated patients achieved an Investigator’s Global Assessment Score (IGA) 0/1 compared with 11% or less with placebo. Adverse events were mild; conjunctivitis occurred less frequently than with agents targeting both IL-4 and IL-13. Relevance to patient care and clinical practice in comparison to existing drugs: As a selective IL-13 inhibitor, lebrikizumab offers comparable efficacy with reduced ocular adverse events relative to dupilumab. Its pharmacologic distinctions from tralokinumab may carry clinical implications.

Conclusion

Lebrikizumab is an effective and well-tolerated biologic with rapid onset of action and favorable safety for treatment of moderate-to-severe AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalDermatitis, AtopicDermatologic AgentsHumansInterleukin-13Severity of Illness IndexAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

Ebglyssatopic dermatitisbiologicsclinical trialsdrug reviewlebrikizumab

Substanzen

Antibodies, MonoclonalDermatologic AgentsInterleukin-13lebrikizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Center for Dermatology Research, Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.

ORCID-Profile: Danial Nasim

Zitieren

APA

Nasim, D., Shaffer, B., & Feldman, S. R. (2026). Lebrikizumab-lbkz for the Treatment of Atopic Dermatitis: A Drug Review. Annals of Pharmacotherapy, 60(7), 710-714. https://doi.org/10.1177/10600280251402987

Vancouver

Nasim D, Shaffer B, Feldman SR. Lebrikizumab-lbkz for the Treatment of Atopic Dermatitis: A Drug Review. Annals of Pharmacotherapy. 2026;60(7):710-714. doi:10.1177/10600280251402987

BibTeX
@article{Nasim2026,
  author = {Nasim, Danial and Shaffer, Brett and Feldman, Steven R},
  title = {Lebrikizumab-lbkz for the Treatment of Atopic Dermatitis: A Drug Review},
  journal = {Annals of Pharmacotherapy},
  year = {2026},
  volume = {60},
  number = {7},
  pages = {710--714},
  doi = {10.1177/10600280251402987}
}
Kostenlos starten →